Programme

Speaker Name

Organisation

Short Title

Hailan Hu

Zhejiang University

Lateral habenula and social dominance

Alan Schatzberg

Stanford University

Where are we with the ketamine-opioid story?

Gerard Sanacora

Yale School of Medicine

Mesmer, Cardiac Surgery, and Ketamine: Appreciating the Power of Contextual Effects

David Nutt

Imperial College London

Psilocybin and ketamine: two sides of the same coin?

Mike Michaelides

National Institute on Drug Abuse

Addiction potential of ketamine enantiomers and metabolites, and of esmethadone

Luke Jelen

King’s College London

Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine (the GO-MARK study)

Theresa Lii

Stanford University

Opioid use diminishes placebo antidepressant response independently of pain in a ketamine depression trial

Amit Anand

Harvard Medical School

Ketamine vs. ECT: implications for clinical practice, policy and future research

Peter van Roessel

Stanford University

RCT of ketamine for OCD

Sophie Holmes

Yale University School of Medicine

RCT of ketamine for depression in Parkinson’s disease

Adriana Feder

Icahn School of Medicine at Mount Sinai

An Open-label Clinical Trial Combining Ketamine Treatment with Written Exposure Therapy for Chronic PTSD

David Mathai

Johns Hopkins

RCT of dextromethorphan vs psilocybin: effects in healthy volunteers with history of hallucinogen use

Shaohua Hu

Zhejiang University School of Medicine

Pilot RCT of ethosuximide in TRD: efficacy and safety

Hans Eriksson

Ketabon

Dose finding study of prolonged release oral ketamine formulation

Daniel Silman

Kings College, London

Keticap immediate release, abuse deterrent: Phase 1 data

Wayne Drevets

Janssen

Long-term safety and durable efficacy of esketamine in TRD and ESCAPE-TRD

Sanjay Mathew

Baylor College of Medicine

EEG gamma oscillations as a prognostic marker for IV ketamine in TRD

Michael Henry

Harvard Medical School

Machine learning to predict response to ECT vs (es)ketamine

Danica Johnson

University of Toronto

Comorbid PTSD and childhood trauma: impact on ketamine’s efficacy in TRD

Christine Ann Denny

Columbia University

Prucalopride (5HT4a agonist) plus ketamine: additive effects on stress

Raag Airan

Stanford University

Targeted ketamine delivery to the thalamus using ultrasound

Chiye Aoki

New York University

Mouse model of anorexia: effects of ketamine in adults and adolescents

Lilian Weber

University of Oxford

Influence of ketamine on the effect of expectations on perceptual and emotional learning

Rupert McShane

University of Oxford

Prospective tracking of bladder symptoms in long term ketamine treatment

Laith Alexander

Kings College London

Anatomy of Melancholy – revision of neuroanatomy relevant to depression

David Feifel

University of California

IV and subcutaneous R-Ketamine for TRD: phase 1 and 2a (Perception)

Colleen Loo

University of New South Wales

Cost-utility analysis of treatment initiation with subcutaneous ketamine for TRD from the KADS Study

Steve Levine

Compass Pathways

Implementation of emerging psychedelics: models of support and interventional psychiatry

Marco Fabus

University of Oxford

Routine electroencephalogram monitoring during ketamine antidepressant treatment in Oxford: preliminary results

Robert Schoevers

University of Groningen

Ketamine-assisted psychotherapies: a systematic review and historical overview

Julia Aepfelbacher

University of Pittsburgh

Experiences of awe mediate ketamine’s antidepressant effects: an RCT in TRD

Zoe Cormier

Author and Journalist

Jonathan Javitt

NRX Pharmaceuticals

From neurotoxicity to neuroplasticity: a lifesaving drug that must be used with respect

Celia Morgan

University of Exeter

Psychological mechanisms of change in ketamine treatment: findings of two mechanistic studies

Patrick Oliver

MindPeace Clinics

IV ketamine: RWE following induction

George Wohlford

University of Virginia

Machine learning predictors of response to ketamine in 1047 patients

Shahar Almog

University of Florida

The misuse potential of medicinal (off-label) ketamine: RWE in the US

Morgan Hardy

RAF Lakenheath

Ketamine for depression and PTSD in the military: an untapped opportunity?

Tiago Gill

Centro de Cetamina

IV esketamine in TRD – RWE following induction

Joost Breeksema

University of Groningen

Between fear and stillness. Patient experiences of oral esketamine for TRD

Johanna Keeler

King’s College London

Ketamine for depression with Anorexia Nervosa: the EDEN study

Rachel Galaska

Oakwood Labs

Development of a ketamine long-acting injectable microsphere formulation

Esther Lukasiewicz Hagai

Clexio Bioscience

Adjunctive CLE-100 esketamine tablet for MDD: a phase 2 RCT during COVID

Rebecca Harding

UCL

500 heavy ketamine recreational users

Erdem Pulcu

University of Oxford

7T imaging of reward loss and shock 24h after ketamine

Meng Li

Jena University Hospital

7T structure, spectroscopy & fMRI up to 24h post IV ketamine dose in 80 healthy volunteers

Nooshin Javaheripour

Jena University Hospital

The immediate and delayed- effects of ketamine on brain functional dynamics

Jolien Veraart

Groningen University

Oral esketamine for bipolar TRD : an open label treatment programme

Jeanine Kamphuis

Groningen University

Oral esketamine as an alternative for maintenance ECT in TRD: case series

Gerard Marek

Gilgamesh Pharma

Dose finding and target engagement of GM-1020, an oral NMDA-R antagonist

Speaker Name / Organsiation / Short Title

– Hailan Hu
– Zhejiang University
– Lateral habenula and social dominance

– Alan Schatzberg
– Stanford University
– Opioid-dependent mechanisms of ketamine antidepressant action

– Gerard Sanacora
– Yale School of Medicine
– Mesmer, ketamine and cardiac surgery: mechanisms of non-specific effects

– David Nutt
– Imperial College London
– Glutamatergic changes with psilocybin, 5HT changes with ketamine, and comparison of circuit level changes

– Mike Michaelides
– National Institute on Drug Abuse
– Addiction potential of ketamine enantiomers and metabolites, and of esmethadone

– Luke Jelen
– King’s College London
– Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine (the GO-MARK study)

– Theresa Lii
– Stanford University
– Opioid use diminishes placebo antidepressant response independently of pain in a ketamine depression trial

– Amit Anand
– Harvard Medical School
– Ketamine vs. ECT: implications for clinical practice, policy and future research

– Peter van Roessel
– Stanford University
– RCT of ketamine for OCD

– Sophie Holmes
– Yale University School of Medicine
– RCT of ketamine for depression in Parkinson’s disease

– Adriana Feder
– Icahn School of Medicine at Mount Sinai
– Pilot RCT of ketamine + Written Exposure Therapy for PTSD

– David Mathai
– Johns Hopkins
– RCT of dextromethorphan vs psilocybin: effects in healthy volunteers with history of hallucinogen use

– Shaohua Hu
– Zhejiang University School of Medicine
– Pilot RCT of ethosuximide in TRD: efficacy and safety

– Hans Eriksson
– Ketabon
– Dose finding study of prolonged release oral ketamine formulation

– Daniel Silman
– Kings College, London
– Keticap immediate release, abuse deterrent: Phase 1 data

– Wayne Drevets
– Janssen
– Long-term safety and durable efficacy of esketamine in TRD and ESCAPE-TRD

– Sanjay Mathew
– Baylor College of Medicine
– EEG gamma oscillations as a prognostic marker for IV ketamine in TRD

– Michael Henry
– Harvard Medical School
– Machine learning to predict response to ECT vs (es)ketamine

– Danica Johnson
– University of Toronto
– Comorbid PTSD and childhood trauma: impact on ketamine’s efficacy in TRD

– Christine Ann Denny
– Columbia University
– Prucalopride (5HT4a agonist) plus ketamine: additive effects on stress

– Raag Airan
– Stanford University
– Targeted ketamine delivery to the thalamus using ultrasound

– Chiye Aoki
– New York University
– Mouse model of anorexia: effects of ketamine in adults and adolescents

– Lilian Weber
– University of Oxford
– Influence of ketamine on the effect of expectations on perceptual and emotional learning

– Rupert McShane
– University of Oxford
– Prospective tracking of bladder symptoms in long term ketamine treatment

– Laith Alexander
– Kings College London
– Anatomy of Melancholy – revision of neuroanatomy relevant to depression

– David Feifel
– University of California
– R-Ketamine for Treatment Resistant Depression

– Colleen Loo
– University of New South Wales
– Cost-utility analysis of treatment initiation with subcutaneous ketamine for TRD from the KADS Study

– Steven Levine
– COMPASS Pharmaceuticals
– Implementation of emerging psychedelics: models of support and interventional psychiatry

– Marco Fabus
– University of Oxford
– Routine electroencephalogram monitoring during ketamine antidepressant treatment in Oxford: preliminary results

– Robert Schoevers
– University of Groningen

– Julia Aepfelbacher
– University of Pittsburgh

– Zoe Cormier
– Author and Journalist

– Jonathan Javitt
– NRX Pharmaceuticals
– Ketamine from Neurotoxicity to Neuroplasticity: A lifesaving drug that must be used with respect

– Celia Morgan
– University of Exeter
– Psychological mechanisms of change in ketamine treatment: findings of two mechanistic studies

– Patrick Oliver
– MindPeace Clinics
– IV ketamine: RWE following induction

– George wohlfold
– University of Virginia
– Machine learning predictors of response to ketamine in 1047 patients

– Shahar Almog
– University of Florida
– The misuse potential of medicinal (off-label) ketamine: RWE in the US

– Morgan Hardy
– RAF Lakenheath
– Ketamine for depression and PTSD in the military: an untapped opportunity?

– Tiago Gill
– Centro de Cetamina
– IV esketamine in TRD – RWE following induction

– Joost Breeksema
– University of Groningen
– Between fear and stillness. Patient experiences of oral esketamine for TRD

– Johanne Keeler
– King’s College London
– Ketamine for depression with Anorexia Nervosa: the EDEN study

– Rachel Galaska
– Oakwood Labs
– Development of a ketamine long-acting injectable microsphere formulation

– Esther Lukasiewicz Hagai
– Clexio Bioscience
– Adjunctive CLE-100 esketamine tablet for MDD: a phase 2 RCT during COVID

– Rebecca Harding
– UCL
– A500 heavy ketamine recreational users

– Erdem Pulcu
– Univeristy of Oxford
– 7T imaging of reward loss and shock 24h after ketamine

– Meng Li
– Jena University Hospital
– 7T structure, spectroscopy & fMRI up to 24h post IV ketamine dose in 80 healthy volunteers

– Nooshin Javaheripour
– Jena University Hospital
– The immediate and delayed- effects of ketamine on brain functional dynamics

– Jolien Veraart
– Groningen University
– Oral esketamine for bipolar TRD : an open label treatment programme

– Jeanine Kamphuis
– Groningen University
– Oral esketamine as an alternative for maintenance ECT in TRD: case series

– Gerard Marek
– Gilgamesh Pharma
– Dose finding and target engagement of GM-1020, an oral NMDA-R antagonist

KETAMINE 2024

Please contact the Secretariat:

Contact us